Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics (OTCQB: SEOVF) generates frequent news as a clinical-stage regenerative medicine company advancing its Cell Pouch Bio-hybrid Organ platform for type 1 diabetes (T1D) and other chronic diseases. Its announcements focus on clinical progress, scientific collaborations, financing activities, and corporate developments that shape the trajectory of its T1D and thyroid disorder programs.
News releases from Sernova highlight interim data from its ongoing Phase 1/2 clinical trial in T1D, including reports of islet engraftment in the Cell Pouch, insulin production indicated by C-peptide, achievement of insulin independence in some patients, and improvements in HbA1c and patient-reported quality-of-life measures. These updates are central for readers tracking how the Cell Pouch Bio-hybrid Organ performs in people living with T1D, particularly those with hypoglycemia unawareness and severe hypoglycemic episodes.
Investors and observers can also follow collaborations and partnerships, such as Sernova’s agreements with Evotec for stem cell-derived islet-like clusters and with Eledon Pharmaceuticals to evaluate the immunosuppressive agent tegoprubart in a future cohort of its T1D trial. In addition, Sernova regularly reports on financing transactions, including loans, convertible debentures, and debt-to-equity conversions, which the company states are used to support working capital and clinical development plans.
Corporate governance and leadership changes, conference presentations, and updates from the company’s Data and Safety Management Board (DSMB) also appear in Sernova’s news flow. This page aggregates these items so readers can review clinical milestones, partnership developments, and capital structure updates related to Sernova Biotherapeutics and its SEOVF listing in one place.
Sernova Biotherapeutics (SEOVF) has received DSMB approval to advance its Phase 1/2 clinical trial for type 1 diabetes treatment using the Cell Pouch™ Bio-hybrid Organ system. The trial's Data and Safety Management Board has authorized enrollment of the final patient in Cohort B, with plans to progress to Cohort C in H2 2025.
The primary endpoint focuses on demonstrating safety and tolerability of islet transplantation into Cell Pouch for T1D patients with hypoglycemia unawareness. The company reports being on track to achieve this endpoint based on current clinical data.
The Cell Pouch™ system, described as the only implantable and retrievable cell containment system for islet engraftment in U.S. clinical trials, has shown islet cell survival in patients ranging from one to five years, with demonstrated ability to support insulin independence. Following trial completion, Sernova plans to initiate a new clinical trial using iPSC islet-like clusters in collaboration with Evotec.
Sernova Biotherapeutics (OTCQB: SEOVF) has appointed Dr. Pericles (Perry) Calias as Chief Development Officer and Head of R&D. Dr. Calias brings over 20 years of global operational experience in drug product development, having previously held leadership positions at Revolo Biotherapeutics, Cerecor Inc., Sucampo Pharmaceuticals, and Shire HGT.
Dr. Calias will contribute to advancing Sernova's Cell Pouch Bio-hybrid Organ, which is being developed as a functional cure for type 1 diabetes (T1D). His expertise includes securing regulatory approvals, leading R&D efforts, patent applications, clinical operations, and advancing therapies in rare diseases, autoimmune disorders, CNS disorders, and drug-device combinations.
He holds a Ph.D. in Bio-Organic Chemistry from Tufts University and is an inventor on over 40 domestic and foreign patents. His experience includes successful regulatory filings of INDs, CTAs, PMAs, BLAs, and NDAs.
Sernova Biotherapeutics (SEOVF) has secured a CAD$1 million unsecured convertible debenture financing from board member Dr. Steven Sangha. The debenture, maturing on March 4, 2027, carries a 15% interest rate and is convertible into common shares at CAD$0.20 per share.
The company also issued 5 million non-transferable share purchase warrants, exercisable at CAD$0.20 per share until March 4, 2028. The financing proceeds will be used for working capital. The transaction, classified as a 'related party transaction,' is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
Sernova Biotherapeutics (SEOVF) has received FDA clearance for its Investigational New Drug (IND) application to evaluate the Cell Pouch bio-hybrid organ with auto-transplanted thyroid cells in patients undergoing thyroid surgery. The therapy aims to treat hypothyroidism in patients post-thyroid surgery.
The Cell Pouch system, combined with autologous thyroid cell therapy, is designed to restore natural thyroid function without requiring thyroid hormone replacement medications or immune suppression therapy. Preclinical studies have shown successful restoration of primary thyroid hormones (T4 and T3) to pre-thyroidectomy levels when thyroid tissue was re-implanted into the pre-vascularized Cell Pouch. Healthy, functional thyroid tissue was confirmed through radio-isotope imaging and histological analysis up to five months post-implantation.
Sernova Biotherapeutics (SEOVF) has submitted an Investigational New Drug (IND) application to the FDA for its Cell Pouch bio-hybrid organ with autologous thyroid cells to treat hypothyroidism in patients undergoing total thyroidectomy. The technology aims to restore natural thyroid function without requiring immune suppression therapy.
Preclinical trials have shown promising results, demonstrating that reimplanting thyroid tissue into the pre-vascularized Cell Pouch restored thyroxine (T4) and triiodothyronine (T3) hormones to pre-thyroidectomy levels without hormone supplementation. Imaging and histology confirmed functional thyroid tissues within the Cell Pouch five months post-reimplantation.
Upon FDA clearance, Sernova plans to initiate a first-in-human clinical trial to evaluate safety, tolerability, and efficacy in patients undergoing thyroidectomy for benign nodular disease.
Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) has appointed Ross Haghighat as Chair of the Board. Haghighat brings over three decades of experience in founding, funding, and scaling technology ventures in healthcare, with expertise in driving successful innovations, strategic growth, and mergers and acquisitions in the biotechnology sector.
The company, which focuses on developing Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), also announced its corporate continuance from the Canada Business Corporations Act to the Business Corporations Act (British Columbia). Additionally, the company has changed its name from Sernova Corp. to Sernova Biotherapeutics Inc., while maintaining its existing ticker symbols.
Sernova Corp. (TSX: SVA, OTCQB: SEOVF, FSE/XETRA: PSH) announced the results of its annual and special general meeting held virtually on January 10, 2025. A total of 74,190,067 common shares were voted, representing 22.8% of all outstanding shares as of November 12, 2024.
Key resolutions approved include the election of six directors: Tanya Lewis (99.6% for), Bernd Muehlenweg (99.7% for), David Paterson (99.4% for), Jonathan Rigby (99.4% for), Steven Sangha (99.4% for), and Ross Haghighat (99.5% for). KPMG LLP was appointed as auditors until the next annual meeting. Other approved resolutions include the continuance as a British Columbia , adoption of new articles, alteration of the share structure to add unlimited Preferred Shares, and an increase in the maximum number of common shares reserved for stock option grants to 50,000,000.
A conditional grant of 5,500,000 options was also approved for officers under the Option Plan. Jonathan Rigby, Sernova’s President and CEO, expressed gratitude for the shareholders' support, emphasizing the company's strengthened management team, new corporate branding, and reinvigorated corporate culture.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) has rescheduled its annual general and special meeting of shareholders from January 7, 2025, to January 10, 2025, at 1:00pm ET. The postponement is due to a recent postal strike in Canada, which affected the company's ability to mail meeting materials through Canada Post to meet regulatory requirements. The record date remains November 12, 2024.
Shareholders must submit their proxies by 1:00 p.m. ET on January 8, 2025, either through TMX Trust Company, by telephone, or online. The Management Information Circular is available on Sernova's website and SEDAR+ profile.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) announced key strategic initiatives, including a non-binding letter of intent with HealthGena and GOLDTRACK Ventures for 'Project REEM Ventures' to explore product development and commercialization opportunities in Saudi Arabia for type 1 diabetes treatment. The company also welcomed Dr. Robert Gabbay, former Chief Scientific and Medical Officer at the American Diabetes Association, as a clinical advisor. Sernova will host a virtual Town Hall on December 13 and hold its Annual General Meeting on January 7, 2025. The company is developing a Cell Pouch bio-hybrid organ as a potential functional cure for type 1 diabetes and thyroid disorders.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) has announced positive interim data from its ongoing Phase I/II clinical trial of the Cell Pouch Transplant System for type 1 diabetes (T1D). The trial shows sustained insulin independence in all 6 patients of Cohort A after islet transplantation. Notably, histological data from a patient's explanted Cell Pouch after 5+ years revealed abundant, well-vascularized, functioning islets producing insulin, glucagon, and somatostatin. The Cell Pouch demonstrated no evidence of fibrosis or degradation after long-term implantation. Sernova plans to complete Cohort B soon and initiate Cohort C with an optimized immune suppression regimen. The company is also developing iPSC-derived islet-like clusters with partner Evotec for a scalable cell source.